Tirzepatide 60mg

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist — a single molecule that activates both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptors simultaneously. This dual mechanism represents a significant advancement over single-target GLP-1 agonists.

Tirzepatide is one of the most studied compounds in recent pharmaceutical history, with extensive clinical trial data from the SURPASS and SURMOUNT programmes demonstrating unprecedented efficacy in metabolic research. It has received FDA approval as Mounjaro (diabetes) and Zepbound (weight management).

Kyrolab supplies tirzepatide across 6 dosage variants from 10mg to 60mg, with independent COA verification across multiple suppliers and dose levels. This is the most comprehensively verified compound in our catalogue.

⚗️ Purity Verification
Independently Verified Purity: 99.878% — Highest Tirzepatide Purity
Tested by Janoshik Analytical (Prague) — Task #87694, 12 November 2025.
Actual content: 63.83mg per vial (6% overfilled vs stated 60mg dose).
This is the highest purity Tirzepatide result across all our testing — 99.878%.
Verification: janoshik.com/verify — Key: VGU6RR9Y3A2G

Specifications

Molecular Weight	4813.45 g/mol
CAS	2023788-19-2
Receptor	Dual GIP/GLP-1R agonist
Half-life	~5 days (preclinical)
Appearance	White lyophilised powder
Storage	2-8°C, protect from light
Dose	60mg per vial

⚗️ Research Use Only
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.